More evidence supporting Gilead Sciences Inc. and its partner Galapagos NV's jointly developed JAK1 selective kinase inhibitor has come in the form of positive results from filgotinib's first pivotal trial in rheumatoid arthritis - results that analysts say effectively de-risk the investigational therapy.
Filgotinib, which is being developed for multiple indications, achieved the primary endpoint in the FINCH 2 late-stage study evaluating it...